Adoptive T cell therapy: engineering and biomanufacturing chimeric antigen receptor-T cell. (December 2018)

• Record Type: Journal Article
• Authors: Jenkins, Jackson; Park, Jaeyoung; Petersen, Kristen; Shajihan, Kahmil; Kruthiventi, Srivalli; Betenbaugh, Michael
• Is Part Of: Current opinion in chemical engineering. Volume 22(2018)
• Page Start: 26
• Page End: 33
• Publication Date: 2018-12
• Subjects: Chemical engineering -- Periodicals; Chemical engineering; Periodicals; 660.05
• DOI: 10.1016/j.coche.2018.08.006
• Languages: English
• ISSNs: 2211-3398

Abstract

Graphical abstract: Highlights: The parameters for CAR-T cell manufacturing should be optimized for scale-up. Correct control of key parameters is crucial for high concentrations of CAR T cells. Engineered CAR-T cells secreting armor agents are promising in treating tumor cells. Abstract : Development of Chimeric Antigen Receptor (CAR)-T cells is revolutionizing the field of cell therapy. Since its inception, research has been focused on improving the effectiveness, accessibility, and safety of CAR-T cell therapy. To achieve this, the biomanufacturing process must be scaled and optimized to match increasing demand. The current processes of engineering, activating, expanding, and purifying CAR-T cells have improved in recent years, but significant challenges in process scaleup and consistency remain. Additionally, engineering efforts now aim to enhance CAR-T cell therapy with 'armored' CAR-T cells to improve solid tumor penetration and immune system response to cancer. This review highlights the current processes and challenges in biomanufacturing and engineering CAR-T cells to improve its success in cancer treatment.